We continue to favour Ergomed’s hybrid business model of services provision and co-development, which provides low-risk exposure to a number of ongoing drug development programmes. We expect important newsflow on two co-development deals in Q4 in the form of interim Phase III data, which if positive would provide further validation for Ergomed’s co-development strategy and de-risk its expected returns.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Near-term newsflow from co-development deals
- Published:
01 Oct 2015 -
Author:
N+1 Singer Team -
Pages:
4
We continue to favour Ergomed’s hybrid business model of services provision and co-development, which provides low-risk exposure to a number of ongoing drug development programmes. We expect important newsflow on two co-development deals in Q4 in the form of interim Phase III data, which if positive would provide further validation for Ergomed’s co-development strategy and de-risk its expected returns.